Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Beam Therapeutics Inc., Medpace Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Beam Therapeutics Inc., Medpace Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Beam Therapeutics Inc., Medpace Holdings and Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Latest Biotechnology and Beam Therapeutics Inc., Medpace Holdings, Inc. Stock News

As of September 1, 2026, Beam Therapeutics Inc. had a $2.9 billion market capitalization, compared to the Biotechnology median of $282.5 million. Beam Therapeutics Inc.’s stock is up 5.7% in 2026, down 3% in the previous five trading days and up 77.38% in the past year.

Currently, Beam Therapeutics Inc. does not have a price-earnings ratio. Beam Therapeutics Inc.’s trailing 12-month revenue is $156.0 million with a -55.4% net profit margin. Year-over-year quarterly sales growth most recently was -94.1%. Analysts expect adjusted earnings to reach $-4.454 per share for the current fiscal year. Beam Therapeutics Inc. does not currently pay a dividend.

As of September 1, 2026, Medpace Holdings, Inc. had a $16.3 billion market cap, putting it in the 84th percentile of all stocks. Medpace Holdings, Inc.’s stock is up 5.6% in 2026, down 4.2% in the previous five trading days and up 22.65% in the past year.

Currently, Medpace Holdings, Inc.’s price-earnings ratio is 34.2. Medpace Holdings, Inc.’s trailing 12-month revenue is $2.8 billion with a 17.7% net profit margin. Year-over-year quarterly sales growth most recently was 17.2%. Analysts expect adjusted earnings to reach $17.705 per share for the current fiscal year. Medpace Holdings, Inc. does not currently pay a dividend.

How We Compare Beam Therapeutics Inc., Medpace Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Beam Therapeutics Inc., Medpace Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Beam Therapeutics Inc., Medpace Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Beam Therapeutics Inc.	BEAM	F
Medpace Holdings, Inc.	MEDP	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Beam Therapeutics Inc. has a Value Score of 14, which is Ultra Expensive. Medpace Holdings, Inc. has a Value Score of 16, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Beam Therapeutics Inc., Medpace Holdings or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Beam Therapeutics Inc., Medpace Holdings or Inc. is the better investment when it comes to value.

Beam Therapeutics Inc., Medpace Holdings and Inc.’s Quality Grades

Company	Ticker	Quality
Beam Therapeutics Inc.	BEAM	D
Medpace Holdings, Inc.	MEDP	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Beam Therapeutics Inc. has a Quality Score of 24, which is Weak. Medpace Holdings, Inc. has a Quality Score of 77, which is Strong.

The Quality Grade Winner: Medpace Holdings, Inc.

As you can clearly see from the Quality Grade breakdown above, Medpace Holdings, Inc. has a better overall quality grade than Beam Therapeutics Inc.. For investors who are looking for companies with higher quality than others in the same industry, Medpace Holdings, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Beam Therapeutics Inc., Medpace Holdings and Inc.’s Momentum Grades

Company	Ticker	Momentum
Beam Therapeutics Inc.	BEAM	B
Medpace Holdings, Inc.	MEDP	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Beam Therapeutics Inc. has a Momentum Score of 79, which is Strong. Medpace Holdings, Inc. has a Momentum Score of 77, which is Strong.

The Momentum Grade Winner: It’s a Tie!

Looking at the Momentum Grade breakdown above, both Beam Therapeutics Inc., Medpace Holdings and Inc. have a grade of B. For those who focus solely on a company’s momentum, further research will need to be conducted into both companies to see if they fit your individual needs as an investor.

Other Beam Therapeutics Inc., Medpace Holdings and Inc. Grades

In addition to Momentum, Quality and Value, A+ Investor also provides grades for Growth and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Beam Therapeutics Inc., Medpace Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Beam Therapeutics Inc., Medpace Holdings or Inc. Stock?

Overall, Beam Therapeutics Inc. stock has a Value Score of 14, Momentum Score of 79 and Quality Score of 24.

Medpace Holdings, Inc. stock has a Value Score of 16, Momentum Score of 77 and Quality Score of 77.

Comparing Beam Therapeutics Inc., Medpace Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.